Skip to content

Regulation of LPL in patients with the metabolic syndrome

Regulation of LPL in patients with the metabolic syndrome - LPL and MetS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34217
Enrollment
60
Registered
2010-08-10
Start date
2010-08-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fat in blood high cholesterol

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient with metabolic syndrome will have to meet at least three of the following criteria (HTG will be a mandatory criteria). o Central obesity; WC > 94 cm in male and > 80 cm in female o Elevated plasma triglycerides 2.0-6.0 mmol/L o Fasting plasma glucose (FPG)

Exclusion criteria

Exclusion criteria: * BMI >32 * Cardiovascular disease * Current use of the following medications: Heparin, or other blood diluting medication * Hepatic dysfunction * End stage renal disease * History of bleeding or recent surgical intervention

Design outcomes

Primary

MeasureTime frame
Differences between cases and controls for: Plasma cholesterol, triglycerides, LDLc, HDLc, apoAI, apoB, apoCII, apoE, apoCIII, ApoAV and ANGPLT 3 and 4 mRNA expression and protein concentration of LPL, GPIHBP1 and ANGPTL4 in adipose tissue mRNA expression and protein concentration of LPL, GPIHBP1 and ANGPTL4 in muscle tissue Histological examination of adipose tissue using antibodies against LPL, GPIHBP1 and ANGPTL4. Histological examination of muscle tissue using antibodies against LPL, GPIHBP1 and ANGPTL4

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)